NATCO Pharma to introduce Hepatitis C drug in Nepal
March 16, 2015: With over 30 years of expertise in innovative dosage forms, NATCO pharma has been a reliable source for the manufacture and supply of active pharmaceutical agents across several countries in the world. Its production facilities are compliant with Good Manufacturing Practices, and has been approved by various drug regulatory bodies including the US FDA, Australian TGA, Korean Health Authority, and the German Health Authority.
NATCO’s specialty lies in the manufacture of products in the antineoplastic, antidepressant, anti migraine, proton pump inhibitors and peptide drugs.
Based in Hyderabad, NATCO has recently launched Gilead Sciences’ drug Sofosbuvir, intended to cure chronic Hepatitis C. After having signed the license with this US based pharmaceutical firm, NATCO will now introduce Sofosbuvir, under the brand name Hepcinat in Nepal. Gilead, and 5 other pharmaceutical players are planning a launch of their own brands in India soon.
The primary reason for the launch of the generic version of this drug, was due to the exorbitant pricing of the original brand. Presently, this drug is priced at US $300 for 28 tablets, which completes one cycle in the management of Hepatitis C.
With the drug being launched in Nepal, NATCO expects a revenue of approximately Rupees 7 crores, of which a 7% royalty will have to be paid to Gilead. Once the Drug Controller of India clears the drug for launch in India, NATCO, along with several other Indian drug manufacturers will compete with the pricing of Sofosbuvir.
Hepatitis C is an infectious disease affecting the liver caused by the Hepatitis C virus. It spreads mainly by blood to blood contact as a result of sharing intravenous needles, and improperly sterilized medical equipment. Antivirals are the primary line of treatment, which cures approximately 80% of the infected population. Cirrhosis is a condition associated with Hepatitis C, and thus prompt medical treatment is essential in order to prevent further complications and expensive liver transplant surgeries.
Dr. Jay Shinde